To assess the correlations between XPD polymorphisms and neuroblastoma risk in particular subgroups of healthy individuals and neuroblastoma patients, we conducted analyses after stratifying based on age, gender, sites of origin, and clinical stages. This evidence concerns the gene ERCC2 and neuroblastoma.